Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Insights on the downsides of late-night screen time and health benefits of digital detox April 27, 2024 Inequities in COVID-19 vaccination coverage for older adults highlighted in global study November 13, 2024 Housing affordability for new mothers may help stave off postpartum depression March 7, 2024
Insights on the downsides of late-night screen time and health benefits of digital detox April 27, 2024
Inequities in COVID-19 vaccination coverage for older adults highlighted in global study November 13, 2024